Related Experiment Videos
Ethnic minority under-representation in clinical trials. Whose responsibility is it anyway?
1Centre for Research in Primary Care, University of Leeds, Leeds, UK.
Abstract:
Ethnic minority people are frequently under-represented in clinical trials. This potentially affects the generalisability/external validity of the trial findings. This not only has important repercussions regarding the safety and the efficacy of new drug use in ethnic minority groups, but also reduces opportunities for subgroup analysis. There can be no scientific basis for excluding this group of people from clinical trials. Aims to provide a mix of theoretical and empirical debates, in order to make sense of ethnic minority exclusion from clinical trials, and suggest possibility of change. Recommends that educational programmes should be directed at clinical trial investigators and funding bodies, to increase their awareness of under-representation of ethnic minority people in clinical trials. Ethics committees could also redress this inequality by providing guidance for investigators, and by being more rigorous about reviewing clinical trial protocols. Provides a set of guidelines to "enlighten" and aid health professionals in working with ethnic, linguistic and culturally diverse populations. The guidelines require additional work and have cost implications. Argues that cost should not be allowed as an acceptable excuse for excluding ethnic minority people from clinical trials.
Insights
Ethnic minority under-representation in clinical trials impacts drug safety and efficacy. Addressing this requires education for investigators and stricter ethics review, not cost excuses.
Area of Science:
- Clinical Trials
- Health Equity
- Medical Research
Background:
- Ethnic minority populations are significantly under-represented in clinical trials.
- This under-representation compromises the generalizability and external validity of trial findings.
- It also limits crucial subgroup analyses, impacting safety and efficacy assessments for diverse groups.
Purpose of the Study:
- To analyze the exclusion of ethnic minorities from clinical trials.
- To propose actionable strategies for increasing their inclusion.
- To debate theoretical and empirical aspects of this under-representation.
Main Methods:
- Review of theoretical and empirical debates on ethnic minority exclusion.
- Analysis of current practices in clinical trial recruitment and protocol review.
- Development of recommendations for stakeholders.
Main Results:
- Exclusion of ethnic minorities from clinical trials lacks scientific basis.
- Educational programs for investigators and funding bodies are recommended.
- Ethics committees play a vital role in ensuring equitable representation.
Conclusions:
- Increased awareness and rigorous protocol review by ethics committees are essential.
- Guidelines for working with diverse populations should be implemented.
- Financial cost should not justify the exclusion of ethnic minorities from clinical trials.